Emulate, Inc., a leading provider of next-generation in vitro models, today welcomed the U.S. Food and Drug Administration's (FDA) newly announced plan to reduce reliance on animal testing in ...
Emulate, Inc., the leading provider of next-generation in vitro Organ-Chip models, today announced the release of its new Chip-R1™ Rigid Chip, designed to minimize drug absorption and enhance ...
The last few weeks have been busy for Jim Corbett. Corbett, the CEO of organ-chip developer Emulate, has been fielding requests from potential clients, as well as from early investors who say they ...
BELLEVUE, Wash.--(BUSINESS WIRE)--EMulate Therapeutics, Inc. (“Emulate”) announces the Open Journal of Biophysics (OJBIPHY), publisher of over 200 peer-reviewed open access journals, has accepted its ...
Researchers are increasingly turning to organ-on-a-chip technology for drug testing and other applications. In a clean room in his lab, Sean Moore peers through a microscope at a bit of intestine, its ...
Lorna Ewart has long been frustrated by the mismatch between animal and human toxicity data. All too often preclinical studies in rats and dogs will suggest a drug is safe, only for clinical trial ...
Historical data indicate that animal models are not ideal for the determination of the efficacy and safety of human therapeutics. Ninety percent of drugs that pass animal studies do not receive ...
Michael Ellenberger, Aydin Harston Ph.D. The FDA Modernization Act 2.0, enacted in December 2022, amended the Federal Food, Drug, and Cosmetic (FD&C) Act to eliminate the requirement for animal ...
insights from industryJim CorbettCEOEmulate, Inc. In this interview, NewsMedical speaks with Jim Corbett, CEO of Emulate, Inc., about the development and impact of the AVA Emulation System and how it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results